The Insight Partners Latest Research for Report “Hemophilia Treatment Market to 2027” Focuses Global Analysis and Forecasts by Product (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytic Agents); Disease (Hemophilia A, Hemophilia B, Hemophilia C); Treatment Type (On-demand, Prophylaxis); Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, Antibody Therapy); End User (Hospitals, Clinics, Ambulatory Surgical Centres, Others) and Geography
‘Hemophilia treatment Market – Global Analysis and Forecasts by Product, Disease, Treatment Type, Therapy, and End User, the global hemophilia treatment market is expected to reach US$ 20,507.92 Mn in 2027 from US$ 12,797.36 Mn in 2019.
Download PDF Sample Copy at:
https://www.theinsightpartners.com/sample/TIPRE00008241/
The market is estimated to grow with a CAGR of 6.1% from 2020-2027. The report highlights the trends prevalent in the global hemophilia treatment market and the factors driving the market along with those that act as deterrents to its growth. The market is expected to grow due to rise in favorable government initiatives and increasing prevalence of hemophilia are expected to upsurge the market growth. However, lack of reimbursement for hemophilia treatment is likely to hamper the growth of the market.
Hemophilia treatments refers to surgical supplies that helps to control blood loss and consists of hemophilia treatment agents present in the form of pads, sponges, patches, powders, liquids or others. Factors such as increasing number of surgical procedures, increasing incidence of sports injuries and technological advancements in hemophilia treatments are expected to account for the growth of the market.
Market Leaders:
The most notable market participants are Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd.,Kedrion S.P.A.,CSL Limited, Biotest AG,Pfizer Inc., Novo Nordisk A/S, Octapharma AG,Baxter International Inc occupying a considerable share of the market owing to their offerings to the market.
Market leaders are involved in inorganic activities such as partnerships and acquisitions in order to improve their performance and consolidate market position. For instance, in March 2018, Sanofi has completed the acquisition with Bioverativ Inc., This acquisition is likely to provide a strong position in the large and growing hemophilia market and expands our presence in specialty care
Prominent players in hemophilia treatments market are also focusing on organic strategies such as product launch, product approval, geographic and manufacturing expansion, and others. These strategies are helping major players to strengthen their market positions along with widening their geographic footprints. Additionally, various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market.
Have a Call with Analyst:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00008241/
Few of the important key developments from the industry are mentioned below:
2019: Roche launched its product Emicizumab under the brand name Hemlibra in India for preventive treatment of Haemophilia A, an inherited disorder in which a person’s blood does not clot properly.
2018: Bayer AG, received US Food and Drug Administration (FDA) approval for its product Jivi, this product is likely to decrease the effect of hemophilia.
2020: Novo Nordisk launched an antihemophilic product nmaely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.
Segments – By product
The hemophilia treatment market by product is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, desmopressin. In 2019, the plasma derived coagulation factor concentrates segment held a largest market share of the hemophilia treatment market. This segment is also expected to dominate the market in 2027. The large share of plasma derived coagulation factor concentrates based hemophilia treatment can be attributed to various advantages offered by these hemophilia treatment, deep market penetration and variety of products offered by multiple players to suit diverse medical application. On the other hand, the recombinant coagulation factor concentrates segment is anticipated to witness the highest growth rate during the forecast period. Certain factors such as effectiveness of the hemophilia treatment in lesser time and better efficient blood clotting are expected to drive the segment growth.
Buy Report at:
https://www.theinsightpartners.com/buy/TIPRE00008241/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876